Table 4.
Distribution of risk scores and risk classification for LNM in the cohort
| Total points | Total patients (N = 335) | LNM (N = 62) | Rate of LNM, % | 95% CI, % |
| 0 | 25 | 0 | 0.0 | 0.0–13.3 |
| 1 | 46 | 1 | 2.2 | 0.1–11.3 |
| 2 | 22 | 2 | 9.1 | 1.6–27.8 |
| 3 | 1 | 0 | 0.0 | 0.0–94.9 |
| 4 | 61 | 5 | 8.2 | 3.6–17.8 |
| 5 | 77 | 12 | 15.6 | 9.2–25.3 |
| 6 | 34 | 8 | 23.5 | 12.4–40.0 |
| 7 | 13 | 5 | 38.5 | 17.7–64.5 |
| 8 | 34 | 13 | 38.2 | 23.9–55.0 |
| 9 | 22 | 16 | 72.7 | 51.9–86.9 |
| Risk category | Total points | Total patients (N = 335) | LNM (N = 62) | Rate of LNM, % | 95% CI, % |
| Low | 0 to 2 | 93 | 3 | 3.2 | −0.4 to 6.9 |
| Intermediate | 3 to 6 | 172 | 25 | 14.5 | 9.2 to 19.9 |
| High | 7 to 9 | 69 | 34 | 49.3 | 37.8 to 60.8 |
LNM, lymph node metastasis.